Phase IV Trial Opens: QiLin AI System vs Standard Care for Anti-VEGF Treatment Decisions in Retinal Disease — What Ophthalmologists Need to Know

References

1. 1.Shanghai General Hospital. (2024). An Artificial Intelligence System for Anti-VEGF Treatment Decisions in Retinal Diseases: A Randomized Controlled Trial. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07328776
2. 2.Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014). Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology, 98(9), 1144-1167. https://doi.org/10.1136/bjophthalmol-2013-304637
3. 3.Holz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., Bogumil, T., Heah, T., Sivaprasad, S., & LUMINOUS Study Group. (2015). Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology, 99(2), 220-226. https://doi.org/10.1136/bjophthalmol-2014-305327
4. 4.Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., Kim, R. Y., & MARINA Study Group. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1419-1431. https://doi.org/10.1056/NEJMoa054481
5. 5.Wells, J. A., Glassman, A. R., Ayala, A. R., Jampol, L. M., Aiello, L. P., Antoszyk, A. N., Arnold-Bush, B., Baker, C. W., Bressler, N. M., Browning, D. J., Elman, M. J., Ferris, F. L., Friedman, S. M., Melia, M., Pieramici, D. J., Sun, J. K., Beck, R. W., & Diabetic Retinopathy Clinical Research Network. (2015). Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England Journal of Medicine, 372(13), 1193-1203. https://doi.org/10.1056/NEJMoa1414264
6. 6.Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018). Age-related macular degeneration. The Lancet, 392(10153), 1147-1159. https://doi.org/10.1016/S0140-6736(18)31550-2
7. 7.Comparison of Age-related Macular Degeneration Treatments Trials Research Group. (2012). Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology, 119(7), 1388-1398. https://doi.org/10.1016/j.ophtha.2011.09.032
8. 8.Wong, W. L., Su, X., Li, X., Cheung, C. M., Klein, R., Cheng, C. Y., & Wong, T. Y. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health, 2(2), e106-e116. https://doi.org/10.1016/S2214-109X(13)70145-1